HDAC6 is a Specific Deacetylase of Peroxiredoxins and is Involved in Redox Regulation

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Jul 9

PMID 18606987

Citations 147

Authors

R B Parmigiani

W S Xu

G Venta-Perez

H Erdjument-Bromage

M Yaneva

P Tempst

P A Marks

Affiliations

Soon will be listed here.

Abstract

Eighteen histone deacetylases (HDACs) are present in humans, categorized into two groups: zinc-dependent enzymes (HDAC1-11) and NAD(+)-dependent enzymes (sirtuins 1-7). Among zinc-dependent HDACs, HDAC6 is unique. It has a cytoplasmic localization, two catalytic sites, a ubiquitin-binding site, and it selectively deacetylases alpha-tubulin and Hsp90. Here, we report the discovery that the redox regulatory proteins, peroxiredoxin (Prx) I and Prx II are specific targets of HDAC6. Prx are antioxidants enzymes whose main function is H(2)O(2) reduction. Prx are elevated in many cancers and neurodegenerative diseases. The acetylated form of Prx accumulates in the absence of an active HDAC6. Acetylation of Prx increases its reducing activity, its resistance to superoxidation, and its resistance to transition to high-molecular-mass complexes. Thus, HDAC6 and Prx are targets for modulating intracellular redox status in therapeutic strategies for disorders as disparate as cancers and neurodegenerative diseases.

Citing Articles

Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein-Protein Interactions.

Asaad L, Pepperrell B, McErlean E, Furlong F Int J Mol Sci. 2025; 26(3).

PMID: 39941046 PMC: 11818932. DOI: 10.3390/ijms26031274.

Histone deacetylase 6 inhibition promotes microtubule acetylation and facilitates autophagosome-lysosome fusion in dystrophin-deficient mdx mice.

Agrawal A, Clayton E, Cavazos C, Clayton B, Rodney G Acta Physiol (Oxf). 2024; 241(1):e14243.

PMID: 39422111 PMC: 11680461. DOI: 10.1111/apha.14243.

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis.

Cheng H, Jiang S, Cai J, Luo Z, Li X, Feng D Front Cell Dev Biol. 2024; 12:1426508.

PMID: 39193364 PMC: 11347278. DOI: 10.3389/fcell.2024.1426508.

Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs.

Zhang W, Jiao B, Yu S, Zhang C, Zhang K, Liu B CNS Neurosci Ther. 2024; 30(5):e14745.

PMID: 38715326 PMC: 11077000. DOI: 10.1111/cns.14745.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.

Karati D, Mukherjee S, Roy S Med Oncol. 2024; 41(4):84.

PMID: 38438564 DOI: 10.1007/s12032-024-02303-x.

References

Koo K, Lee S, Jeong S, Kim E, Kim H, Kim K . Regulation of thioredoxin peroxidase activity by C-terminal truncation. Arch Biochem Biophys. 2002; 397(2):312-8. DOI: 10.1006/abbi.2001.2700. View

Zou H, Wu Y, Navre M, Sang B . Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun. 2006; 341(1):45-50. DOI: 10.1016/j.bbrc.2005.12.144. View

Ungerstedt J, Sowa Y, Xu W, Shao Y, Dokmanovic M, Perez G . Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102(3):673-8. PMC: 543461. DOI: 10.1073/pnas.0408732102. View

Noh D, Ahn S, Lee R, Kim S, Park I, Chae H . Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001; 21(3B):2085-90. View

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani R . Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther. 2007; 6(9):2525-34. DOI: 10.1158/1535-7163.MCT-07-0251. View

Engel R, Evens A . Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci. 2005; 11:300-12. DOI: 10.2741/1798. View

Xu W, Parmigiani R, Marks P . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37):5541-52. DOI: 10.1038/sj.onc.1210620. View

Arner E, Holmgren A . Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000; 267(20):6102-9. DOI: 10.1046/j.1432-1327.2000.01701.x. View

Petri S, Kiaei M, Kipiani K, Chen J, Calingasan N, Crow J . Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2005; 22(1):40-9. DOI: 10.1016/j.nbd.2005.09.013. View

10.

Moon J, Hah Y, Kim W, Jung B, Jang H, Lee J . Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin isotype II that enhances HeLa cell resistance to H2O2-induced cell death. J Biol Chem. 2005; 280(31):28775-84. DOI: 10.1074/jbc.M505362200. View

11.

Iwata A, Riley B, Johnston J, Kopito R . HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005; 280(48):40282-92. DOI: 10.1074/jbc.M508786200. View

12.

Hockly E, Richon V, Woodman B, Smith D, Zhou X, Rosa E . Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003; 100(4):2041-6. PMC: 149955. DOI: 10.1073/pnas.0437870100. View

13.

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

14.

Powis G, Mustacich D, Coon A . The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med. 2000; 29(3-4):312-22. DOI: 10.1016/s0891-5849(00)00313-0. View

15.

Lee W, Choi K, Riddell J, Ip C, Ghosh D, Park J . Human peroxiredoxin 1 and 2 are not duplicate proteins: the unique presence of CYS83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2. J Biol Chem. 2007; 282(30):22011-22. DOI: 10.1074/jbc.M610330200. View

16.

Sauve A, Wolberger C, Schramm V, Boeke J . The biochemistry of sirtuins. Annu Rev Biochem. 2006; 75:435-65. DOI: 10.1146/annurev.biochem.74.082803.133500. View

17.

Kovacs J, Murphy P, Gaillard S, Zhao X, Wu J, Nicchitta C . HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005; 18(5):601-7. DOI: 10.1016/j.molcel.2005.04.021. View

18.

Pandey U, Batlevi Y, Baehrecke E, Taylor J . HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy. 2007; 3(6):643-5. DOI: 10.4161/auto.5050. View

19.

Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y . Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2004; 13(11):1183-92. DOI: 10.1093/hmg/ddh131. View

20.

Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R . Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem. 2002; 277(22):19396-401. DOI: 10.1074/jbc.M106585200. View